• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
pharmaceutical pricing
December 3, 2020 by Global Pricing Innovations (GPI)
Spain will Require Pricing & Cost of Treatment Data for HTA submissions from Next Year: 2021, the Year of Data?

Recently Spain’s medicines regulatory bodies announced the requirement of additional “economic evaluation” data for therapeutics positioning reports (IPTs) which is the equivalent of a Health Technology Assessment process in the country. This change is part of a revolution of the overall HTA process…

February 7, 2020 by Global Pricing Innovations (GPI)
Pfizer’s newest range of biosimilars are set to significantly undercut Roche’s ‘best-selling’ Avastin, Herceptin, and Rituxan on pricing. What will be the impact on Roche’s market share?

Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…

How will Pfizer's discounted biosimilars affect Roche?
New Head Office Location Announcement
January 22, 2020 by Global Pricing Innovations (GPI)
Global Pricing Innovations announces relocation of London Head office

London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…

January 2, 2020 by Global Pricing Innovations (GPI)
Pharmaceutical industry offers large medicine discounts in the Philippines

In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…

Global Pricing Innovations Pharmaceutical Industry
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs
October 25, 2019 by Global Pricing Innovations (GPI)
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs

Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…

October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
Novartis building
October 18, 2019 by Global Pricing Innovations (GPI)
Novartis’s gene therapy Luxturna receives ‘considerable added benefit’ in Germany

  Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…

October 1, 2019 by Global Pricing Innovations (GPI)
Pharma price and access pioneers, Global Pricing Innovations (GPI), continue growth with the strategic expansion to Cambridge, UK.

New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support.   London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…

September 23, 2019 by Global Pricing Innovations (GPI)
With the Updated Stability Programme 2019-2022, Spanish government reinforces healthcare budget control measures

In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…

August 30, 2019 by Global Pricing Innovations (GPI)
Roche’s Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe.

  Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…

August 27, 2019 by Global Pricing Innovations (GPI)
Italy’s drug pricing reform in trouble as Prime Minister Conte resigns

  On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…

August 23, 2019 by Global Pricing Innovations (GPI)
US Government is considering introduction of International Reference Pricing

President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…

August 19, 2019 by Global Pricing Innovations (GPI)
Canada finalises new regulations to tackle high drug prices

  Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…

June 10, 2019 by Global Pricing Innovations (GPI)
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement?

  Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…

June 4, 2019 by Global Pricing Innovations (GPI)
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation.

Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.

June 3, 2019 by Global Pricing Innovations (GPI)
Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA

  The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…

May 15, 2019 by Global Pricing Innovations (GPI)
New set of rules regulating medicine prices in Kazakhstan

  New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…

May 7, 2019 by Global Pricing Innovations (GPI)
Malaysian authorities approve the introduction of IRP

  Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…

April 18, 2019 by Global Pricing Innovations (GPI)
New IRP rule introduced in Greece

International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…

April 8, 2019 by Global Pricing Innovations (GPI)
Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices

By Alexandros Soumalevris, GPI     Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…

February 25, 2019 by Global Pricing Innovations (GPI)
Employee Spotlight – Tom Brockbank

  Tom Brockbank Consultant Joined GPI in May 2018 This weeks Employee Spotlight focuses on Tom Brockbank.  Tom is a part of the core consultancy team based in our London office, whom help to guide our clients consulting requests on a daily basis….

March 3, 2017 by Global Pricing Innovations (GPI)
International Reference Pricing Reforms

Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through…

February 6, 2017 by Global Pricing Innovations (GPI)
Egypt: Drug Price Hikes Highlight Market Volatility

With the largest population in the Middle East and North Africa region, Egypt has attracted a strong presence from multinational pharmaceutical companies. However, current turmoil over drug shortages and drug price hikes underscores the volatility of a market characterised by high out-of-pocket spending….

October 3, 2016 by Global Pricing Innovations (GPI)
AMNOG and the German Reforms: What Will Change?

By Preeti Patel and Sophie Schmitz on Oct 3, 2016  We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial…

Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121